Metavia Presents Pre-Clinical Data On Da-1241 Demonstrating Additive Hepatoprotective Effects In Combination With Efruxifermin At The ADA's 85Th Scientific Session

MetaVia Inc MTVA:

• METAVIA PRESENTS PRE-CLINICAL DATA ON DA-1241 DEMONSTRATING ADDITIVE HEPATOPROTECTIVE EFFECTS IN COMBINATION WITH EFRUXIFERMIN AT THE ADA'S 85TH SCIENTIFIC SESSION

• METAVIA INC - COMBINATION THERAPY DECREASES INFLAMMATORY AND FIBROTIC GENE EXPRESSION

• METAVIA INC - COMBINATION THERAPY REDUCES INFLAMMATORY AND FIBROTIC PROTEINS IN THE LIVER